Mitomics launches flagship product - Prostate Core Mitomic Test.

Mitomics announced on 31 Mar 2011 the launch of its flagship product, the Prostate Core Mitomic Test (PCMT), a revolutionary new test that uses the science of mitochondrial DNA (mtDNA) to accurately determine the absence or presence of cancerous cells using previously obtained prostate biopsy tissue. PCMT is available through the company's state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) lab in Aurora, CO. In anticipation of this launch, Mitomics has been building its US sales team, hiring key members that will support the marketing of PCMT in initial target markets of Baltimore, Boston, Cleveland, Philadelphia and Chicago. Utilizing its cancerization field effect to …